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                                                                   ABSTRACT 
BACKGROUND 
               Chronic periodontitis is primarily an infection wherein pro-inflammatory 
cytokines are instrumental in host mediated tissue destructive immune response. 
Among the cytokines, Tumor necrosis factor-α (TNF-α) has been considered to cause 
insulin resistance. In type-2 diabetes mellitus, insulin resistance is the main etiological 
factor which is linked to decreased serum adiponectin level, which has been found 
recently. Many studies have hypothesized that non-surgical periodontal therapy 
improves glycemic control and adiponectin level in type-2 diabetes mellitus with 
chronic periodontitis. 
AIM 
To evaluate the effect of non-surgical periodontal therapy on serum 
adiponectin level in Type-II diabetic patients with moderate to severe chronic 
periodontitis. 
METHODS 
          50 systemically healthy age & gender matched controls with healthy 
periodontium and 50 type-2 diabetes mellitus patients with moderate to severe chronic 
periodontitis were enrolled. Venous blood samples were collected at baseline from 
100 subjects (Control group and Study group-I) and 3 months after the non-surgical 
therapy from diabetic patients with moderate to severe chronic periodontitis (Study 
group-II). Serum level of adiponectin was analysed by Enzyme linked immunosorbent 
assay (ELISA). 
RESULTS 
       The study group-II showed significant (p=0.000) improvement in clinical 
periodontal parameters 3 months after the non-surgical therapy. After 3 months, 
Fasting blood sugar level was significantly (p=0.000) decreased and serum 
adiponectin level was significantly (p=0.000) increased (8.39µg/mL) in study group-II 
compared to those in the study group-I (7.52µg/mL). 
CONCLUSION 
            In the present study, type-2 diabetes mellitus patients with moderate to severe 
chronic periodontitis exhibited improvement compared to baseline value. Non-
surgical periodontal therapy improves fasting blood sugar level with elevation of 
serum adiponectin level in type-2 diabetic patients with moderate to severe chronic 
periodontitis. 
Key words: Adiponectin, Chronic periodontitis, Type-2 diabetes mellitus  
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                                                     INTRODUCTION 
Diabetes mellitus is a metabolic disorder characterized by altered glucose 
tolerance and impaired lipid and carbohydrate metabolism. More than 300 million 
people worldwide will have diabetes by 2025 and at least 366 million people will 
have diabetes by 2030
43
. Diabetes mellitus is one among the systemic conditions that 
can aggravate the progression of chronic periodontitis.  Chronic periodontal disease is 
considered to be the sixth complication of diabetes mellitus
27
.  
Chronic inflammatory periodontal disease represents a primarily anaerobic 
gram-negative oral infection that leads to gingival inflammation, destruction of 
periodontal tissue, loss of alveolar bone and eventually loss of teeth in severe cases. 
The endotoxin of these micro-organisms induce pro-inflammatory cytokines such as 
Tumor necrosis factor-α (TNF-α), Interleukin-6 (IL-6) and are instrumental in 
generating a host-mediated tissue destructive immune response.  
Studies
3, 7, 40
 have established that adipose tissue is no longer a fatty tissue and 
it does produce many cytokines, grouply named as ‘adipokines’. Among adipokines, 
adiponectin is a protein hormone or cytokine of 30-KDa complement-related protein 
(Acrp 30), exclusively produced by adipose tissue
7
. Adiponectin is a insulin-
sensitizing hormone with anti-diabetic, anti-inflammatory and anti-atherosclerotic 
properties
46
. 
The etiology of type-2 diabetes mellitus is insulin resistance in spite of hyper 
insulinemia, there is increased hyperglycemia. Increased release and activity of serum 
C-reactive protein (CRP) and Tumor necrosis factor-α (TNF-α) are mainly considered 
to be responsible for the development and progression of insulin resistance in type-2 
diabetes mellitus. Adiponectin has been thought to be associated with insulin 
_________ _________________________________________________________Introduction 
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resistance
21 
and plays an important negative regulatory role in some physiological and 
pathological processes
53
. Few studies
8,22,36,50
 have been done regarding initial 
periodontal treatment for type-2 diabetes patients with moderate to severe chronic 
periodontitis to evaluate the impact on pro-inflammatory cytokines, glycemic control 
and serum adiponectin level. 
Hence, the present study was undertaken to evaluate the effects of non-
surgical periodontal therapy on serum adiponectin levels in type-II diabetes mellitus 
patients with moderate to severe chronic periodontitis. 
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                                           AIM AND OBJECTIVES 
The aim of the study was to evaluate the effect of non-surgical periodontal 
therapy on serum adiponectin level in Type-II diabetic patients with moderate to 
severe chronic periodontitis. 
For this purpose the following objectives were undertaken:  
1. To estimate the level of adiponectin in type-II diabetic patients with moderate to 
severe chronic periodontitis. 
2. To investigate the effect of non-surgical therapy on serum adiponectin level as a 
marker of insulin resistance. 
3. To correlate and compare the serum adiponectin level with blood sugar level and 
periodontal status of type-II diabetes mellitus patients with moderate to severe 
chronic periodontitis before and after treatment.  
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                                                 REVIEW OF LITERATURE 
                                                          ADIPONECTIN 
                    HISTORICAL BACKGROUND AND GENERAL PROPERTIES 
          In 1992, Grimshaw et al
14
, stated that mice fed with omega-3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have shown increased 
plasma adiponectin levels.  Furthermore, Berberine is an herbal folk medicine, which 
also has been shown to increase adiponectin expression which partly explains its 
beneficial effects on metabolic disturbances. 
Lodish et al. 1995
26
 identified a secretory protein from murine 3T3-L1 
adipocytes and named it adipocyte complement-related protein of 30 kDa (Acrp30). It 
is a structural homolog to complement factor C1q and to a hibernation-specific 
protein isolated from the plasma of Siberian chipmunks. It forms large homo-
oligomers that undergo a series of post-translational modifications. 
          Scherer PE et al. 1995
40
 observed that the adiponectin is a 147 amino acid 
protein and consisits of four distinct regions. The first is a short signal sequence that 
targets the hormone for secretion outside the cell; next is a short region that varies 
between species; the third is a 65-amino acid region with similarity to collagenous 
proteins; the last is a globular domain. Overall this gene shows similarity to the 
complement 1q factors (C1q). It possesses a short N-terminal variable region followed 
by several collagen repeats (Gly-X-Y) and finally a large C-terminal globular domain. 
            Maeda K et al. 1996
30
 assessed the human adiponectin gene which was 
cloned through systematic sequencing of an adipose-tissue library. The apM1 gene 
encodes a 244 amino acid open reading frame, containing a putative signal sequence 
   ____________________________________________________________Review of Literature 
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repeat (66 amino acids) followed by a cluster of aromatic residues near the C terminus 
having high local resemblance to collagens X and VIII and complement factor C1q. 
          Based on SDS-PAGE1 and crystallographic studies, structure of adiponectin 
appears to form a variety of higher order structures. Also Shapiro L et al. 1998
41
 
demonstrated that the adiponectin monomers assemble into homotrimers with the 
three globular domains adjacent to one another and the three collagen-like regions 
forming a collagen triple helix. These trimers then assemble into hexamers and other 
high molecular weight (HMW) complexes. 
          In 1999, a group at Osaka University
3
 isolated the human adipose-specific 
transcript, the apM1 gene product, which was found to be a soluble matrix protein, 
and named it adiponectin. It was identified as a distinct protein among the adipokines 
because the plasma concentration of adiponectin decreases upon accumulation of 
visceral fat. 
          In 2003, a group from Japan
51
 isolated complementary DNAs encoding the 
adiponectin receptors 1 and 2(AdipoR1 and AdipoR2) by expression cloning. These 
two adiponectin receptors have seven-transmembrane domains, but they are distinct 
from the topology of G-protein-coupled receptors. The AdipoR1 gene encodes for a 
375-amino-acid protein with an estimated molecular mass of 42.4 kDa, whereas 
AdipoR2 encodes for a 311-amino-acid protein of 35.4 kDa. 
          Waki et al. 2003
47
 described that the various adiponectin species affect liver 
hepatocytes and skeletal muscle myocytes differently. Only the high molecular weight 
(HMW) multimer and the hexamer forms of adiponectin act on hepatocytes via AMP-
activated protein kinase (AMPK) to inhibit glucose production and reduce 
intracellular triglycerides (TGs) and insulin resistance. By contrast, the Cys39ser 
mutant trimer and globular domain mutants, as well as all wild-type adiponectin 
   ____________________________________________________________Review of Literature 
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species, act on myocytes via AMPK to stimulate glucose uptake and reduce 
intracellular TGs and insulin resistance.  
          Wang J et al. 2004
48
 revealed that the T-cadherin is an adiponectin-binding 
protein through subsequent DNA analysis. T-cadherin is a unique cadherin molecule 
that lacks the transmembrane and cytoplasmic domains and is bound to the surface 
membrane through a glycosylphosphatidylinositol (GPI) anchor and it can bind to the 
hexameric and HMW forms of adiponectin but not to monomer globular and trimeric 
forms. T-cadherin is ubiquitously expressed, with the highest expression found in the 
heart and the aortic, carotid, iliac, and kidney arteries and it is critical for the 
association of adiponectin protection against cardiac stress in mice. 
           Nedvídkova J et al. 2005
34
 showed that the gene was localized to chromosome 
3q27, a region highlighted as affecting genetic susceptibility to type-2 diabetes and 
obesity. The gene was investigated for variants that predispose to type–2 diabetes. 
Several single nucleotide polymorphisms in the coding region and surrounding 
sequence were identified from several different populations, with varying prevalence, 
degrees of association and strength of effect on type-2 diabetes.  
           Choi BH et al. 2009
7
 revealed that the adiponectin (also known as GBP28, 
apM1, Acrp30, or AdipoQ) is a 244-residue protein that is produced largely by white 
adipose tissue (WAT). Adiponectin has structural homology with collagens VIII and 
X and complement factor C1q, and circulates in the blood in relatively large amounts 
in different molecular forms. Furthermore, adiponectin circulates in the bloodstream 
in trimeric, hexameric, and high-molecular-mass species, while different forms of 
adiponectin have been found to play distinct roles in the balance of energy 
homoeostasis    
   ____________________________________________________________Review of Literature 
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ASSOCIATION BETWEEN ADIPONECTIN AND TYPE-2 DIABETES 
MELLITUS, PERIODONTITIS  
 
           Uysal et al. 1997
46
 observed that the adiponectin mainly affects insulin 
receptors which are a part of insulin sensitivity cascade rather than HbA1c level and 
plays an important negative regulatory role in some physiological and pathological 
processes including multiple protective roles such as anti-diabetic, anti-atherosclerotic 
and anti-inflammatory factors. It regulates glucose and lipid metabolism, improves 
insulin sensitivity, reduces hepatic glucose production  and also they stated that the 
hypoadiponectinemia is correlated with increased insulin resistance during the 
development Type-2 Diabetes mellitus. 
           Hotta et al. 2000
16
 reported that adiponectin is a novel, adipose-specific 
protein abundantly present in the circulation, and it has anti-atherogenic properties. 
Plasma levels of adiponectin in the diabetic subjects without CAD were lower than 
those in nondiabetic subjects. The plasma adiponectin concentrations of diabetic 
patients with CAD were lower than those of diabetic patients without CAD. 
Significant, univariate, inverse correlations were observed between adiponectin levels 
and fasting plasma insulin (r=-0.18, P<0.01) and glucose (r=-0.26, P<0.001) levels. 
These results suggested that the decreased plasma adiponectin concentrations in type-
2 diabetes patients compared with non-diabetic. 
Imagawa A et al. 2002
19
 stated that the serum adiponectin levels are elevated 
in type I diabetic patients (ie: patients with reduced levels of circulating insulin) as 
well as in patients with genetically defective insulin receptors when compared with 
healthy controls. Furthermore, hyperinsulinaemia significantly lowers plasma 
adiponectin levels under euglycaemic conditions. In addition, the HMW form of 
   ____________________________________________________________Review of Literature 
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adiponectin is selectively down-regulated in hyperinsulinaemia and type II diabetes. It 
is possible that insulin may activate some signaling pathways that indirectly suppress 
adiponectin biosynthesis and secretion.  
           Yamauchi T et al. 2002
52
 confirmed that adiponectin (Ad) is a hormone 
secreted by adipocytes that regulates energy homeostasis and glucose and lipid 
metabolism. Further, they showed that phosphorylation and activation of the 5'-AMP-
activated protein kinase (AMPK) are stimulated with globular and full-length Ad in 
skeletal muscle and only with full-length Ad in the liver. In parallel with its activation 
of AMPK, Ad stimulates phosphorylation of acetyl coenzyme A carboxylase (ACC), 
glucose uptake and reduction of molecules involved in gluconeogenesis in the liver. 
Blocking AMPK activation by dominant-negative mutant inhibits each of these 
effects, indicating that stimulation of glucose utilization and fatty-acid oxidation by 
Ad occurs through activation of AMPK.  
He W et al. 2003
15
 identified Peroxisome Proliferator- Activated Receptors- γ 
(PPARγ) is a member of the PPAR subfamilies of transcription factors, which is 
expressed mainly in adipose tissue and which is considered to be a positive regulator 
of adiponectin gene expression. Targeted deletion of PPARγ in adipose tissue of mice 
results in marked adipocyte hypocellularity and hypertrophy, elevated levels of 
plasma free fatty acids  and triglyceride, and decreased levels of adiponectin. 
Furthermore, PPARγ increases adiponectin levels and secretion by stimulating the 
expression of proteins involved in adiponectin assembly. 
              Kadowaki et al. 2006
21
 reported that adiponectin, the major adipocyte 
secretory protein, has been thought to be associated with insulin resistance (IR) and 
hypoadiponectinemia, caused by interactions of genetic factors such as SNPs in the 
Adiponectin gene and environmental factors causing obesity, appears to play an 
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important causal role in insulin resistance, type 2 diabetes, and the metabolic 
syndrome, which are linked to obesity. The adiponectin receptors, AdipoR1 and 
AdipoR2, which mediate the antidiabetic metabolic actions of adiponectin, have been 
cloned and are downregulated in obesity-linked insulin resistance. Upregulation of 
adiponectin is a partial cause of the insulin-sensitizing and antidiabetic actions of 
thiazolidinediones.        
Lu HL et al. 2006
29
 showed that plasma adiponectin was associated with the 
disorder of metabolism of glucose and lipid in diabetes. The levels of plasma 
adiponectin was correlated negatively with BMI, blood glucose, insulin resistance 
index and triglyceride (respectively, r=-0.55, P<0.01; r=-0.51, P<0.05; r=-0.52, 
P<0.05; r=-0.39, P<0.05), while it was positively correlated with insulin sensitive 
index (r=0.45, P<0.05). They concluded that the relationship between adiponectin 
hormone and insulin sensitivity suggests that it may take part in the development of 
insulin resistance of type 2 diabetes and levels appear to correlate negatively with 
insulin sensitivity. 
Yamaguchi N et al. 2007
53
 explored the role of adiponectin in the etiology of 
periodontitis using the D clone of RAW264, a clone that exhibits highly efficient 
osteoclast formation, to determine whether adiponectin acts as a regulatory molecule 
in osteoclast formation stimulated by lipopolysaccharide of periodontopathic bacteria. 
Further, they observed that adiponectin acted as a potent inhibitor of osteoclast 
formation stimulated by Toll-like receptor-4 (TLR4) ligand and receptor activator of 
NF-κB ligand (RANKL). These results strongly suggested that adiponectin may 
function as a negative regulator of lipopolysaccharide/RANKL-mediated osteoclast 
formation in periodontal disease. 
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Kopp A et al. 2010
24
 investigated that the mechanisms of Toll-like receptor 
(TLR)-induced prodiabetic and proinflammatory activation of adipocytes. They 
concluded that macrophage activating lipopeptide-2 (MALP-2) is able to induce IL-6 
and monocyte chemoattractant protein-1 (MCP-1) release in adipocytes isolated from 
inflamed adipose tissue, whereas these adipocytes lost their ability to respond to LPS. 
The present results shows a role of the adipose tissue in innate immunity and TLR-
ligand induced proinflammatory and prodiabetic activation of adipocytes might 
couple visceral adipose tissue dysfunction with insulin resistance and type 2 diabetes 
mellitus. 
Reiko Furugen et al. 2010
39
 stated that pro-inflammatory cytokines such as 
TNF-α and IL-6 are induced after stimulation with lipopolysaccharide (LPS) of gram-
negative periodontopathic bacteria. These cytokines increased by the progression to 
severe forms of periodontitis may affect glucose metabolism. Hence, the elevation of 
these cytokines attributable to periodontitis could increase the risk for insulin 
resistance and suppress the adiponectin production leads to reduce insulin sensitivity 
and worsen glycemic control.  
                                                                
                    Figure 1: The relationship among periodontitis and adipokines 
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 Zhang X et al. 2011
54
 stated that on a high-fat diet (HFD), the ap2-dn-JNK 
mice displayed a marked suppression of both JNK1 and JNK2 activation in their 
adipose tissue, accompanied by a marked reduction in weight gain, fat mass, and size 
of the adipocytes. The transgenic mice were resistant to the deleterious impact of an 
HFD on systemic insulin sensitivity, glucose tolerance. These changes were 
accompanied by reduced macrophage infiltration in adipose tissue, decreased 
production of proinflammatory adipokines and increased expression of adiponectin. 
These results concluded that the selective suppression of JNK activation in adipose 
tissue leads to decreased systemic inflammation and increased serum adiponectin 
level. 
Ioanna Xynogala et al. 2012
20
 showed that the serum levels of adiponectin 
were increased in insulin treated diabetic rats in the presence of periodontitis, while 
serum IL-6 levels did not change. Furthermore, adiponectin levels were statistically 
significantly higher at the end of the experiment compared with levels on day 16 in 
the periodontitis group (p<0.01), but did not change in insulin treated diabetic rats 
without periodontitis. 
Dominik Kraus et al. 2012
10
 revealed that adiponectin modulates critical 
effects of lipopolysaccharide (LPS) from P.gingivalis on oral epithelial cells (OECs). 
Gingival tissue sections showed a strong synthesis of adiponectin and its receptors in 
the epithelial layer. Adiponectin abrogated significantly the stimulatory effect of LPS. 
Similarly, it inhibited significantly the LPS-induced decrease in cell viability and 
increase in cell proliferation and differentiation. Also, adiponectin led to a time-
dependent induction of the anti-inflammatory mediators IL-10 and hemeoxygenase-1 
and blocked the LPS-stimulated Nuclear Factor-κB nuclear translocation. 
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 ASSOCIATION BETWEEN PERIODONTITIS AND TYPE-2 DIABETES 
MELLITUS               
            
           Pociot F et al. 1993
37
 stated that the circulating monocytes from diabetic 
patients  exhibit an exaggerated inflammatory response to gram-negative bacterial 
lipopolysaccharides, releasing large amounts of inflammatory mediators and pro-
inflammatory cytokines such as IL-1β, IL-6 and  TNF-α. This hyper responsive 
monocytic phenotype is not associated with hyperglycemia and potential 
predisposition to tissue breakdown. 
Weidman E et al. 1996
49 
reported that individuals with sustained 
hyperglycemia, proteins become irreversibly glycated to form advanced glycation end 
products (AGEs). These stable carbohydrate-containing proteins have multiple effects 
on cell-to-cell and cell-to-matrix interactions and are commonly thought to be a major 
link between the various diabetic complications. The formation of AGEs also occurs 
in the periodontium and higher levels of periodontal AGE accumulation and 
periodontal destruction are found in those with diabetes than in non-diabetic subjects. 
           Loesche WJ et al. 1998
28
 stated severe chronic periodontitis represents a sub-
clinical septicemic state. It can produce some inflammatory cytokines (e.g. CRP, 
TNF-α and IL-6) in the local tissue, as well as elevating their circulating levels. CRP 
is an important mediator of inflammation, mainly synthesized in the liver. TNF-α is 
another important inflammatory cytokine, closely linked to insulin resistance, which 
plays a role in the regulation of CRP expression and both the levels are increased in 
Type – 2 Diabetes patients with periodontitis. 
           Qi C et al. 2000
38
 reported that the elevated levels of TNF-α alter intracellular 
insulin signaling (inhibiting tyrosine kinase activity of insulin receptor) and reduce 
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the synthesis of insulin responsive glucose transporter, creating an insulin resistance 
syndrome similar to insulin resistance that characterizes type-2 diabetes. 
           Hujoel PP et al. 2001
18
 described that the dentogingival surface area (DGES) 
comprises both the sulcular and junctional epithelium, present in health, as well as 
any intervening pocket epithelium present in periodontitis. Individuals without 
periodontitis had a typical DGES of 5 cm
2
. Among individuals with periodontitis, the 
mean DGES in the three samples ranged from 8 cm
2
 (ranging from 1 to 29 cm
2
) to 20 
cm
2
 (ranging from 2 to 44 cm
2
). It was concluded that the mean DGES among 
individuals with periodontitis or the cumulative surface area of ulcerated pocket 
epithelium has been estimated to ranges from 8 to 20 cm
2
, which is approximately the 
size of the palm of an adult hand. 
Arner P et al. 2005
4 
confirmed that the periodontal treatment not only reduces 
clinically evident inflammation, but also improves the glycemic control and reduces 
insulin resistance (IR) and improves β-cell function in type-2 diabetes mellitus 
(T2DM) patients. These findings indicate that inflammation is involved in the 
pathogenesis of IR and T2DM, which is regarded as key processes in the mechanism 
of T2DM. Furthermore, IR plays a central role in the development of T2DM. 
         Nishimura et al. 2005
35
 found that chronic periodontal inflammation can lead 
to increased serum levels of TNF-α, thus inducing the phosphorylation of serine 
residues in the insulin receptor substrate-1, prompting the target cells to produce 
insulin resistance (IR). TNF-α and other inflammatory mediators may activate the 
intracellular pathways, such as the I-kappa-B (IκB), I-kappa-B kinase-β (IκKβ), 
nuclear factor-kappa B (NF-κβ) and the protein c-Jun N-terminal Kinase (JNK) axes, 
amplify and aggravate low-grade inflammation, and these processes may become self-
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perpetuating through a positive feedback loop created by the pro-inflammatory 
cytokines and lead to IR and diabetes. 
Engebretson et al. 2007
11
 suggested that the elevated circulating tumour 
necrosis factor-alpha (TNF-α) may contribute to insulin resistance in patients with 
type 2 diabetes. The source of plasma TNF-α has been thought to be adipocytes 
associated with obesity, but inflammation and infection result in TNF-α production as 
well. Furthermore, chronic periodontitis is associated with plasma TNF-α levels in 
subjects with type-2 diabetes supports the hypothesis that periodontal infection and 
inflammation may contribute to insulin resistance. TNF-α showed a significant 
positive correlation with attachment loss (r=0.40, p=0.009), plasma endotoxin 
(r=0.33, p=0.03). A dose-response relationship was observed between periodontitis 
severity and TNF-α (p=0.012) 
Mealey BL et al. 2008
32
 evaluated that chronic systemic inflammatory state 
induced by periodontal disease which may contribute to insulin resistance through a 
“feed-forward” mechanism that worsens glycemic control. There was a dose-response 
relationship between the severity of PD and serum TNF-α level, which suggested that 
periodontal disease may play a major role in elevating levels of this cytokine, which is 
closely linked to insulin resistance and thereby aggravate metabolic control. 
         Lei Chen et al. 2010
25
 stated chronic periodontitis was associated with 
glycemic metabolic and serum hs-CRP levels in patients with type-2 diabetes. The 
results revealed that an increased mean PD had significantly higher levels of HbA1c 
and hs-CRP (P<0.05) and no significant difference was found among different groups 
in the levels of serum TNF-α , fasting glucose and lipid profiles but, after controlling 
for age, gender, body mass index, duration of diabetes mellitus, smoking, regular 
physical exercise and alcohol consumption positive correlations were found between 
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mean PD and HbA1c (r=0.2272; P=0.009) and between mean PD and hs-CRP 
(r=0.2336; P=0.007). 
EFFECT OF PERIODONTAL TREATMENT ON SERUM ADIPONECTIN 
AND BLOOD GLUCOSE LEVEL          
 
Miller LS et al. 1992
33 
demonstrated that combination of scaling and root 
planing with systemic doxycycline therapy is associated with an improvement in 
periodontal status that is accompanied by significant improvement in glycemic 
control, as measured by the glycated hemoglobin assay (HbA1c) as well as fasting 
plasma glucose level (FPG).             
         Stewart JE et al. 2001
44
 reported that significant improvement in glycemic 
control after treatment. After periodontal therapy, the weighted average decrease in 
absolute HbA1c values was 0.4%, but this was not found to be statistically significant. 
The addition of adjunctive systemic antibiotics to the mechanical therapy regimen 
resulted in an average absolute reduction of 0.7%. Again, this reduction did not 
achieve a level of statistical significance. 
Kiran et al. 2005
23
 showed that non-surgical periodontal treatment is 
associated with improved glycemic control in type-2 diabetes patients. After SRP, 
poorly controlled diabetes patients were reported to exhibit significant reductions in 
glycated haemoglobin (HbA1c) and fasting plasma glucose levels at the 3-month time 
point compared to levels at baseline and 1-month and also exhibit significant 
reductions in PD, PI, BOP and CAL. However, the baseline and 1-month HbA1c 
levels were indifferent for these clinical parameters.  
Furugen R et al. 2008
12
 showed that elderly Japanese people with 
periodontitis (at least one tooth that displayed a probing pocket depth of >6 mm) was 
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significantly associated with higher serum resistin levels and total leukocyte counts. 
No significant differences were observed in adiponectin, IL-6 and TNF-α levels 
between subjects with and without periodontitis, but serum adiponectin tended to 
decrease in patients with periodontitis. 
Debora C et al. 2009
9
 demonstrated that the periodontal therapy improved 
glycemic control in patients with type-2 diabetes. However, the reduction in HbA1c 
values for the group who received full mouth scaling and root planning, was 
statistically significant, but not for the group who received full mouth scaling and root 
planning and antibiotics. The changes in fasting glucose levels were not significant 
for either group. However, the reduction in HbA1c values reached statistical 
significance only in the group received scaling and root planing alone. 
Matsumoto et al. 2009
31
 revealed that anti-microbial periodontal treatment 
(APT) and periodontal maintenance (PM) not only improve periodontal disease but 
also increase serum adiponectin in T2DM patients. Test group received scaling with 
ultrasonic devices at baseline and APT biweekly for 2 months while control group 
received scaling at baseline and mechanical tooth cleaning (MPT) at the same 
interval. At 6 months, all patients received mechanical tooth cleaning as PM. 
Adiponectin concentrations in test group had significantly increased by 31.4% after 
APT (p=0.024) and by 30.4% after PM (p=0.002) compared with baseline. The 
percentage of ≥4 mm probing depths (PD) had shown 8.3% and 9.3% reduction after 
APT and PM (p=0.046, 0.02) in test group while 5.0% reduction after MPT in control 
group. 
           Correa FOB et al. 2010
8
 reported that clinically successful non-surgical 
periodontal therapy tended to reduce systemic inflammation and the concentration of 
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some circulating cytokines. Further, the results showed that all clinical parameters 
(plaque index, gingival bleeding index, bleeding on probing, probing depth and 
clinical attachment level) were significantly improved 3-months after the periodontal 
therapy. A univariate comparison suggested a tendency towards a decrease of the 
measured biomarkers, most pronounced for  TNF-α and FIB, after therapy. 
Periodontal treatment also reduced fasting plasma glucose and  hs-CRP levels, albeit 
not significantly. 
Kardesler L et al. 2010
22
 demonstrated that the patients with type 2 diabetes 
and chronic periodontitis exhibited similar clinical periodontal improvements as their 
systemically healthy counterparts. Initial periodontal treatment appeared to decrease 
fasting plasma glucose (FPG) and HbA1c level, thereby improve glycemic control in 
poorly controlled patients with diabetes. Decreases in levels of IL-6, TNF-α, CRP and 
leptin and an increase in adiponectin levels after periodontal therapy may be a 
function of glycemic control in patients with type-2 diabetes.  
Pariksha Bharti et al. 2011
36
 stated that periodontal treatment improves 
periodontal status and glycemic control with elevation of serum adiponectin in type-2 
diabetes patients. The results suggested that HbA1c is reduced by amelioration of 
insulin resistance due to elevated serum adiponectin after periodontal treatment and 
improvements of PPD and BOP also were observed. Generalized linear model 
revealed that changes of serum adiponectin and TNF-α and change of BOP correlated 
significantly with the reduction of HbA1c at 6 months after periodontal treatment.     
          Wei-Lian Sun et al. 2011
50
 showed that periodontal intervention can improve 
glycemic control, lipid profile and IR, reduce serum inflammatory cytokine levels and 
increase serum adiponectin levels in moderately to poorly controlled T2DM patients. 
The levels of clinical periodontal variables, the probing depth, attachment loss, 
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bleeding index, and plaque index were improved significantly in T2DM-Treated 
group after 3 months compared to T2DM-Non treated group (all p<0.01). After 3 
months, the serum levels of hs-CRP, TNF-α, IL-6, fasting plasma glucose (FPG), 
glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model of 
assessment - insulin resistance (HOMA-IR) significantly decreased and adiponectin 
was significantly increased in T2DM-Treated group compared to those in the T2DM-
Non treated group (p<0.05 or p<0.01).      
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                                          MATERIALS AND METHODS  
 STUDY DESIGN AND SUBJECT SELECTION:  
              The study was approved by the Institutional Ethical Committee. About 100 
subjects in the age group of 35-60 years who attended the outpatient section of 
Department of Periodontics, Tamil Nadu Government Dental College, Chennai 
participated in the study. The patients were divided into 3 Groups, Control group - 50 
subjects with healthy periodontium and Study group - 50  type-2 diabetes mellitus 
subjects with moderate to severe chronic periodontitis, the same study group before 
treatment considered as Study group-I and after treatment considered as Study   
group-II.  
INCLUSION CRITERIA: 
• Patients willing for voluntary participation and signing the informed consent. 
• Age : 35-60 years 
• Gender : Both males and females 
• Healthy subjects: (CONTROL GROUP) 
        a. Probing depth <3mm 
        b. Less than 20% of sites with gingival bleeding 
        c. Fasting blood sugar level 80-110 mg/dl  
        d. Good oral hygiene status with plaque index score less than 1 
        e. Absence of Clinical Attachment Loss as determined by CAL (Clinical 
Attachment Level) measurements i.e. CAL=0 
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• Type-II Diabetes mellitus with moderate to severe generalized chronic 
periodontitis:  (STUDY GOUP-I) 
       a. To obtain physician opinion prior to non surgical periodontal therapy. 
       b. No change in courses of treatment 
           i.e. there was no change in oral anti-diabetic drug 3 months before and during                          
                the study. 
       c. Patients having at least 20 teeth 
       d. ≥ 2 teeth per quadrant, excluding third molars with Probing Pocket Depth              
           ≥5mm.    
       e. Presence of Clinical Attachment Loss as determined by CAL measurements      
           ≥3mm
2
.
  
       f. Patients having greater than 126mg/dl of fasting blood glucose level 
       g. Radiographic evidence of alveolar bone loss 
EXCLUSION CRITERIA: 
• History of Smoking or use of tobacco in any forms 
• History of any systemic diseases except Diabetes Mellitus (Hypertension, 
Cardiovascular diseases and Kidney, Liver or Lung diseases) 
• Patients with a history of periodontal treatment in the past 6 months 
• History or presence of any other chronic infectious diseases 
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• Pregnancy and lactation 
• Alcohol consumption 
STUDY PROTOCOL: 
1. Institutional Ethical Committee approval. 
2. Medical history and Informed consent. 
3. Periodontal examination using clinical parameters namely, Gingival Bleeding 
Index, Plaque Index, Probing Pocket Depth and Clinical Attachment Level. 
4. Orthopantomogram (OPG) for radiographic evaluation of generalized chronic 
periodontitis. 
5. Complete blood count (CBC)  
6. Estimation of Fasting blood glucose (FBS) level by Glucometer.  
7. Collection of blood samples. 
8. Estimation of Adiponectin level in serum by ELISA method. 
             Following selection of subjects, written informed consent was 
obtained after explaining the study procedure. Examination was preceded by a 
thorough medical and dental history of the subjects. Intra-oral examination 
was done using Mouth mirror and William’s periodontal probe. Periodontal 
evaluation was done by measuring Gingival Bleeding Index (GBI), Plaque 
Index (PI), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL) 
and Orthopantomogram (OPG). 
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                              ARMAMENTARIUM 
 
CLINICAL EXAMINATION AND SAMPLE COLLECTION: 
Mouth mirror 
           William’s Periodontal Probe 
Tweezer 
Head cap 
Surgical gloves 
Face mask 
Spirit 
Sterile cotton 
Torniquette 
5ml disposable syringe with 23 gauge disposable needle 
Vaccutainer tubes 
Centrifuge machine 
Micropipette  
Eppendorf tubes 
Thermos box with gel pack 
One-touch Horizon Glucometer 
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 FOR NON-SURGICAL PERIODONTAL THERAPY: 
Mouth mirror 
Explorer 
Tweezer 
Scalers and Curettes  
Kidney Tray 
Cotton Rolls 
Disposable Gloves 
Disposable Facemask 
Disposable Headcap 
Disposable syringe 
Local Anaesthetic solution 
SAMPLE STORAGE: 
-20 ˚C Freezer 
ELISA PROCEDURE: 
Test tubes 
Eppendorf tubes 
Plastic rack 
Autoclaved plastic pipette tips 
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           Micropipette 
ELISA washer 
ELISA reader 
 
                                       PERIODONTAL EXAMINATION 
CLINICAL PARAMETERS: 
GINGIVAL BLEEDING INDEX1: 
            Starting distobuccally, the probe was inserted slightly into the sulcus and run 
to the buccal and mesial surfaces of every tooth at an angle of about 45’. This was 
repeated for all teeth present. Probing was similarly carried out at palatal/lingual sites. 
Any gingival units that exhibited bleeding were recorded. The total number of 
bleeding sites per tooth was recorded for every tooth except the third molars. 
Criteria for scoring: 
          Positive score (+)         -       Presence of bleeding within 10 seconds 
Negative score (-)        -       Absence of bleeding 
                                 
                                  Total number of positive score 
% of bleeding sites =   ----------------------------------------------------     x 100 
                                  Total number of surfaces of all teeth 
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PLAQUE INDEX42 :     
              All teeth were examined at 4 surfaces (disto-facial, facial, mesio-facial, 
lingual/palatal) and were scored as follows 
Criteria for scoring: 
 Score 0   No plaque 
   
 Score 1 
 
Plaque not visible to the naked eye, detected by explorer 
 
 Score 2 
 
Thin to moderate accumulation of soft deposits within the gingival pocket or 
the tooth and gingival margin, visible to the naked eye 
 Score 3 Abundance of soft matter within gingival pocket or on tooth surface and 
gingival margins, inter-dental area stuffed with soft debris 
  
Calculation: 
         Plaque index for the tooth = Total score from 4 areas / 4 
         Plaque index for the individual = Total plaque indices for all teeth /      
                                                                    No. of teeth examined.  
Interpretation: 
         Score   0      -  Excellent oral hygiene 
        0.1 to  0.9   -  Good oral hygiene 
1.0 to  1.9  -   Fair oral hygiene 
2.0 to 3.0   -   Poor oral hygiene 
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PROBING POCKET DEPTH (PPD)13, 6 (mm):    
          Probing Pocket Depth was measured from the gingival margin to the base of the 
pocket using William’s Periodontal Probe. The probe was walked within the gingival 
sulcus along the circumference of the tooth. Six measurements were made per tooth  
                     -   Mesiobuccal, Midbuccal, 
                         Distobuccal, Mesiolingual,  
                         Midlingual, Distolingual. 
CLINICAL ATTACHMENT LEVEL (CAL) 6 (mm):        
• Clinical Attachment Level was measurement from the Cemento – enamel 
junction (CEJ) to the base of the pocket in millimeters using William’s Periodontal 
Probe. Three measurements were made on the buccal aspect and three on the lingual 
aspect of each tooth – total of six sites per tooth such as Mesiobuccal, Midbuccal, 
Distobuccal, Mesiolingual, Midlingual, and Distolingual sites. 
• When the gingival margin was located on the anatomic crown, the level of the 
attachment was determined by subtracting from the probing pocket depth, the distance 
from the gingival margin to the Cemento-Enamel Junction (CEJ). If both were the 
same, the loss of attachment was calculated to be Zero. 
• When the gingival margin coincided with the CEJ, the loss of attachment was 
calculated as equaling the probing pocket depth. 
• When the gingival margin was located apical to the CEJ, the loss of 
attachment was greater than the probing pocket depth and therefore the distance 
between the CEJ and the gingival margin were added to the PPD. 
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FASTING BLOOD SUGAR ESTIMATION:   
         After cleaning of the middle finger of the left hand for each patient using spirit 
and lancet, a drop of blood was obtained and fasting blood glucose level was 
estimated using One-touch Horizon glucometer and recorded. 
BLOOD SAMPLE COLLECTION FOR CONTROL AND STUDY GROUP-1 
(PRE-TREATMENT) SUBJECTS: 
           After skin preparation, 5ml of fasting venous blood sample was obtained from 
each patient by using disposable hypodermic syringe with 23 gauge needle by 
venipuncture without stasis from antecubital fossa between 8.00 to 10.00 AM and 
transferred to a plain vaccutainer tube. The blood sample was allowed to clot for 30 
minutes in the vaccutainer tube and then centrifuged for 15 minutes at 3000 rpm to 
separate the serum. Then 500µL of serum sample was divided in aliquots and stored 
at -20˚C until analysis. 
BLOOD SAMPLE COLLECTION FOR STUDY GROUP - 11 (POST-
TREATMENT) SUBJECTS: 
          Non-surgical periodontal therapy (Scaling and Root planing) was performed 
and the patient was instructed to maintain oral hygiene. After 3 months, periodontal 
status were re-evaluated and blood samples obtained same as previously mentioned 
and then centrifuged for 15 minutes at 3000 rpm to separate the serum. Then 500µL 
of serum sample was divided in aliquots and stored at -20˚C until analysis. 
PROCEDURE FOR ADIPONECTIN ANALYSIS: 
1. ELISA METHOD: 
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The circulating adiponectin, is expressed and secreted exclusively by adipose 
tissue and is measurable in serum by ELISA. 
         In this study Orgenium Human Adiponectin, R&D Laborateries ELISA Kit, 
FINLAND was used. 
Contents of ELISA kit: 
• Adiponectin Microplate (Item A) : 1 plate 
                   96 well polystyrene microplate coated with anti-human Adiponectin.      
• Wash Buffer Concentrate (20x) (Item B) :   
         25ml of 20x concentrated solution. 
• Adiponectin Standards (Item C) : 2 vials     
         80 ng of recombinant adiponectin in a buffered protein base added with 
preservatives. 
• Assay Diluent  A (Item D) : 2 bottles 
         30ml of diluents buffer, 0.09% sodium azide as preservative. 
• Assay Diluent C (Item L) : 2 bottles 
       15ml of diluents buffer 
• Assay Diluent B (Item E) : 
        15ml of 5x concentrated buffer 
• Detection Antibody Adiponectin (Item F) : 2 vials 
        Biotinylated anti-human Adiponectin (each vial is enough to assay half 
microplate). 
• HRP-Streptavidin Concentrate (Item G) : 
         8 µl 4000x concentrated HRP-conjugated streptavidin. 
• TMB one-step color Substrate Reagent (Item H) : 
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         12ml of 3,3’ ,5,5’- tetramethylbenzidine (TMB) in buffer solution. 
• Stop solution (Item I)  : 1 vial 
         8 mL of 2 M sulfuric acid. 
REAGENT PREPARATION: 
1. All reagents and samples allowed to attain room temperature (18- 25˚C). 
2. Sample dilution : 
       A 200 – fold dilution of serum sample was done - 2µl sample + 398 µl Assay 
Diluent A (Item D). 
3. Assay Diluent B should be diluted 5 – fold with deionized or distilled water.  
4. Preparation of standard : 
      The vial of Item C was briefly spined and then added 800 µl Assay Diluent A 
or Assay Diluent C into Item C vial, a 50 µg/ml standard prepared. The powder 
thoroughly mixed and dissolved. Added 180 µl Adiponectin standard (50 µg/ml) 
from the vial of Item C, into a tube with 320 µl Assay Diluent A or Assay Diluent 
C, a 80 µg/ml stock standard solution prepared. The solution was Pipetted 500 µl 
Assay Diluent A or Assay Diluent C into each tube. The stock standard solution 
used to produce a dilution series. Each tube mixed thoroughly before the next 
transfer. Assay Diluent A or Assay Diluent C served as the Zero standard           
(0 µg/ml). 
5. The Detection Antibody vial (Item F) was briefly spined before use. Then added 
100µl of 1 x Assay Diluent B into the vial, a detection antibody concentrate 
prepared. Pipetted up and down and gently mixed. The detection antibody 
concentrate was diluted 80 – fold with 1 x Assay Diluent B and used in step 4 of 
Part VI Assay Procedure. 
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6. The HRP-Streptavidin concentrate vial (Item G) was briefly spined and pipetted 
up and down. HRP-Streptavidin concentrate was diluted 4,000 – fold with 1x 
Assay Diluent B. 
                                    Figure 2: Dilution of adiponectin standard 
 
 
 
 
             80                     8            4             2              1         0.5         0.25        0.125            
          µl/mL             µl/mL     µl/mL     µl/mL     µl/mL    µl/mL   µl/mL    µl/mL 
 
 ASSAY PROCEDURE: 
1.  All reagents and samples were allowed to attain the room temperature before use. 
2.  100 µl of each standard and sample were added into appropriate wells and 
incubated for 2.5 hours at room temperature. 
3. The solution was discarded and washed 4 times with 1 x Wash Solution. Washed 
by filling each well with Wash Buffer (300 µl) using a multi-channel Pipette. After 
the last wash, any remaining Wash Buffer was removed by aspirating or decanting. 
The plate was inverted and blotted against clean paper towels. 
4. Then 100 µl of 1 x prepared biotinylated antibody were added to each well. 
Incubated for 1 hour at room temperature with gentle shaking. 
5. The solution was discarded. The wash step was repeated as in step 3. 
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6. 100 µl of prepared Streptavidin solution were added to each well. Incubated for 45 
minutes at room temperature with gentle shaking. 
7. The solution was discarded. Repeated the wash as in step 3. 
8. Then 100 µl of TMB One-step Color Substrate Reagent (Item H) were added to 
each well. Incubated for 30 minutes at room temperature. 
9. 50 µl of Stop Solution (Item I) were added to each well. The color in the wells 
changed from blue to yellow. 
10. The optical density of each well was determined immediately using a micro plate 
reader set to 450 nm.   
Calculation of results: 
             The optical density of each sample was plotted against its concentration and a 
curve was drawn through the points. Because the samples were diluted, the 
concentrations was read from the standard curve and multiplied by the dilution factor.                     
                                        Figure 3:  Adiponectin standard curve    
                         
                                          Adiponectin Concentration µg/mL 
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ASSAY PROCEDURE SUMMARY: 
Reagents, samples and standards were prepared as instructed 
↓ 
100 µl sample was added to each well. 
Incubated for 2.5 hours at room temperature 
                                     ↓ 
Aspirated and washed four times 
↓                               
100 µl prepared biotin antibody to each well. 
Incubated for 1 hour at room temperature. 
↓     
Aspirated and washed four times 
↓ 
100 µl prepared Streptavidin solution. 
Incubated 45 minutes at room temperature. 
                                     ↓ 
100 µl TMB One-step Substrate Reagent to each well, 
Incubated 30 minutes at room temperature. 
                                     ↓ 
50 µl Stop Solution to each well 
                                     ↓ 
Absorbance read at 450 nm immediately.            
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         Photograph 1 : Healthy periodontium - Control group 
 
     
 
 
                    
                
 
         Photograph 2 : T2DM with Generalised chronic periodontitis - Study     
group-I 
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     Photograph 3 : Measurement of probing depth with 
                 William’s periodontal probe 
 
 
                                
                    
 
                     Photograph 4: Orthopantomogram 
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            Photograph 5: After Non-surgical periodontal therapy – Study group-II   
 
 
 
               
                      
        
        Photograph 6: Armamentarium for periodontal examination 
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                                    Photograph 7: Collection of blood sample 
 
 
 
 
 
                     
 
                   Photograph 8: Collected blood sample 
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                                           Photograph 9: Centrifuge machine 
 
 
 
 
 
 
 
 
 
                  
 
          Photograph 10: Centrifuged serum 
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                 Photograph 11: Serum in Eppendorf microfuge tube 
 
 
 
                    
 
                       Photograph 12: Armamentarium for sample transportation  
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                     Photograph 13 -  C                                
                  
                 
 
                                                                                        
                    
 
       Photograph 14: ELISA kit 
____________________________________________________________Materials and Methods 
40 
 
                     
 
         Photograph 15: ELISA kit contents 
 
 
 
                  
 
             Photograph 16: 96 well microplate of ELISA kit 
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                                            Photograph 17: Micropipette 
 
 
 
 
 
                 
 
    
                  
                 
               Photograph 18: Collected serum samples for assay 
____________________________________________________________Materials and Methods 
42 
 
                    
 
                    Photograph 19: ELISA reader and washer 
 
 
 
 
 
                    
   
                Photograph 20: 96 well microplate on autowasher 
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                    Photograph 21: 96 well microplate with conjugate solution 
 
 
 
 
 
 
 
 
                
 
      Photograph 22: 96 well microplate after adding substrate solution 
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                          Photograph 23: 96 well microplate on ELISA reader 
 
 
 
 
 
 
 
 
 
                           
                      
 
 
 
                Photograph 24: Estimation of fasting blood glucose level by Glucometer 
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                                                STATISTICAL ANALYSIS 
The statistical analysis was done using the computer software program SPSS 
(Statistical Package for Social Sciences) for Windows version 17. 
Mean and Standard Deviation were estimated for different variables in each 
group.  
Mean values were compared between levels before & after treatment using 
Student’s Paired t-test. 
    Pearson’s chi-square test was done to compare the gender distribution 
between the two groups.  
    Kendall’s tau-b rank correlation coefficient test was used to analyze the 
correlation between the clinical parameters, fasting blood sugar level and adiponectin 
level. 
 In the present study, P-value <0.05 was considered as the level of significance.       
 
                    STATISTICAL FORMULAE USED FOR DATA ANALYSIS 
Student’s Paired t-test: 
The Paired t-test was used to compare the statistical significance of a possible 
difference between the means of same group on some dependent variable and the two 
groups were dependent of one another. 
The formula for the Paired t-test was 
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The top of the formula is the sum of the differences (i.e. the sum of d). The bottom of 
the formula reads as:  
The square root of the following: n times the sum of the differences squared minus the 
sum of the squared differences, all over n-1. 
The sum of the squared differences: ∑d2 means take each difference in turn, square it, 
and add up all those squared numbers. 
The sum of the differences squared: (∑d)2 means add up all the differences and 
square the result. 
 The P value or calculated probability was the estimated probability of 
rejecting the null hypothesis (H0) of a study question when that hypothesis was true. 
The smaller the p-value, the more significant the result was said to be. All P-values 
are two tailed, and confidence intervals were calculated at the 95% level. Differences 
between the two populations were considered significant when p < 0.05. 
 
Pearson’s Chi-square Test: 
    The formula used was  
                   
Where O = Observed frequency in a cell 
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           E = Expected frequency in a cell 
Kendall’s tau-b Test: 
Kendall’s tau-b was used to measure the strength of relationship between the 
two variables and the coefficient was used to test for statistical dependence. Values of 
tau-b ranges from −1 (100% negative association or perfect inversion) to +1 (100% 
positive association or perfect agreement).  A value of zero indicates the absence of 
association. 
The Kendall tau-b coefficient is defined as: 
              
Where, 
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                                                            RESULTS 
 
Hundred subjects were included in th is present study. The 
subjects were categorized into three groups  as follows:   
50  subjects with healthy periodontium as the Control group 
50 subjects type-2 diabetes mellitus with moderate to severe generalized chronic            
periodontitis as the Study group and it is considered as the following: 
  Baseline level (Pre-treatment) – Study Group-I 
  After initial treatment (Post-treatment) – Study Group-II         
  
Table 1, 2 and 3 shows the master chart of the control  group, study 
group- I and II with the clinical parameters, fasting blood sugar  level 
and serum adiponectin level .  
 
Table 4 and Figure 4 shows the comparison of age between the study and control 
group.  The mean age in the study group was 46 years and 41 years in the control 
group respectively. There was no statistical  significant difference in the 
distribution of sex  in both the groups.  
 
Table 5 and Figure 5 shows the comparison of gender distribution between the study 
and control group. The males constituted 46% while females constituted 54% in the 
study group. Both males and females constituted about 44% and 56% respectively in 
the control group. There was no statistical s ignificant difference in 
distribution of the gender  between the groups.  
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Table 6 and Figure 6 shows the comparison of clinical parameter mean Plaque Index 
between the study group I and II. The mean Plaque Index score in the study group-I 
was 2.494±0.147 and 1.187 ±0.079 in the study group-II, which was statistically 
highly significant (p=0.000).  
 
Table 6 and Figure 7 shows the comparison of clinical parameter mean % of sites 
with Bleeding on Probing between the study group I and II. The mean % of sites with 
Bleeding on Probing was 90.407±5.385 in the study group-I and 8.563±3.289 in the 
study group-II, which was statistically highly significant (p=0.000). 
 
Table 7 and Figure 8 shows the comparison of mean adiponectin levels between the 
study group I and II. The mean adiponectin levels in serum were 7.52±2.96 µg/mL in 
the study group-I and 8.39±2.52 µg/mL in the study group-II, which was statistically 
highly significant difference in serum adiponectin levels between the study group I 
and II. (p=0.000) 
 
Table 8 and Figure 9 shows the comparison of mean CAL between study group-I 
and study group-II. The mean CAL was 7.54±1.804mm in study group-I and 
2.74±0.655mm in study group-II. There was statistically highly significant difference 
in CAL between study group-I and II. (p=0.000) 
Table 9 and Figure 10 shows the comparison of mean PPD between study group-I 
and study group-II. The mean PPD was 7.13±1.738mm in study group-I and 
2.283±0.423mm in study group-II, which was statistically highly significant 
difference in PPD between study group-I and II. (p=0.000) 
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Table 10 and Figure 11 shows the comparison of mean FBS level between study 
group-I and study group-II. The mean FBS level was 183.20±24.982mg/mL in study 
group-I and 175.20±20.360mg/mL in study group-II. There was statistically highly 
significant difference in FBS level between study group-I and II. (p=0.000)  
Table 11 shows the correlation between the clinical parameters, fasting blood sugar 
level and adiponectin level in both study group I and II. A linear negative correlation 
was found between PPD and adiponectin level in the study group I and II, which was 
statistically highly significant (p=0.000) (Figure 12, 13). A linear negative correlation 
was found between CAL and adiponectin level in the study group I and II, which was 
statistically highly significant (p=0.000) (Figure 14, 15).  A linear negative 
correlation was found between fasting blood sugar level and adiponectin level in the 
study group I and II, which was statistically highly significant correlation  (p=0.000)   
(Figure 16, 17). 
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Table 1: MASTER CHART - CONTROL GROUP 
CASE 
NO 
AGE SEX PI 
% OF 
SITES BOP 
PPD 
(mm) 
CAL 
(mm) 
Adiponectin 
(µg/mL) 
Fasting 
blood 
sugar 
(mg/ml) 
C1 43 M 0.6 5.50 1.9 0 15.1 94 
C2 38 F 0.7 6.60   1.68 0 16.2 90 
C3 41 F 0.7 7.80   1.93 0 15.8 99 
C4 38 F 0.5 4.28   1.30 0 17.1 81 
C5 51 M 0.4 3.99   1.65 0 18.2 94 
C6 45 F 0.5 3.88   1.90 0 19.9 89 
C7 50 M 0.6 10.42   2.27 0 9.1 107 
C8 45 F 0.6 4.46   1.60 0 16.9 89 
C9 50 M 0.6 4.00   2.18 0 9.5 108 
C10 48 F 0.7 4.77   2.28 0 11.9 101 
C11 52 M 0.5 6.82 1.9 0 13.4 99 
C12 48 F 0.6 6.00 1.7 0 14.5 98 
C13 40 F 0.7 4.22 1.6 0 16.7 90 
C14 54 F 0.5 6.48 2.5 0 62 109 
C15 48 F 0.6 5.45 1.6 0 16.6 91 
C16 40 M 0.5 7.93 1.5 0 14.8  93 
C17 46 F 0.6 3.60 1.5 0 18.1 87 
C18 48 M 0.7 6.20 1.6 0 17.0 91 
C19 47 F 0.6 5.50 1.5 0 18.9 88 
C20 36 F 0.7 4.60 1.4 0 17.1 82 
C21 38 M 0.5 5.17 1.7 0 15.1 86 
C22 50 F 0.7 4.00 1.6 0 21.4 84 
C23 45 M 0.6 5.50 1.8 0 14.4 90 
C24 45 F 0.5 6.88 1.9 0 14.9 97 
C25 51 M 0.6 4.70 1.5 0         19.4 82 
C26 39 F 0.5 4.00 1.7 0 16.9 88 
C27 56 F 0.6 7.55 2.0 0 13.9 99 
C28 55 M 0.6 7.94   2.19 0 9.3 106 
C29 37 F 0.5 4.00 1.9 0 17.0 84 
C30 48 M 0.5 7.66 2.3 0 7.0 109 
C31 38 M 0.6 4.09 1.6 0 15.9 82 
C32 36 M 0.5 8.71 1.9 0 15.3 88 
C33 41 M 0.6 4.00 1.5 0 15.8 81 
C34 49 F 0.7 5.50 1.9 0 18.1 86 
C35 38 F 0.7 6.50 1.6 0 17.2 83 
C36 36 F 0.6 9.64 1.9 0 15.9 88 
C37 50 F 0.6 5.40 2.3 0 8.0 108 
C38 51 M 0.5 8.58 2.3 0 7.9 105 
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C50 40  M 0.6 5.00 1.7 0 13.6  94 
 
 
               Table 1 : MASTER CHART - STUDY GROUP – I 
CASE 
NO 
AGE SEX PI % OF 
SITES BOP 
PPD 
(mm) 
CAL 
(mm) 
Adiponectin  
(µg/mL) 
FBS 
(mg/ml) 
SP1 40 F 2.33 78.90 4.10 4.15 13.2 142 
SP2 38 F 2.24 89.06 5.18 5.44 8.9 178 
SP3 43 F 2.07 91.45 6.89 7.94 8.0 185 
SP4 46 F 2.21 85.15 9.21 9.90 3.9 223 
SP5 44 M 2.2 90.62 7.57 8.46 5.1 199 
SP6 45 M 2.3 55.91 6.06 6.17 9.8 162 
SP7 40 M 2.46 87.54 6.22 7.98 9.1 170 
SP8 47 M 2.5 91.40 9.39 9.99 3.7 221 
  SP09 43 M 2.42 65.33 8.16 8.90 5.2 190 
  SP10 45 F 2.44 81.67 6.00 7.99 9.6 169 
  SP11 38 F 2.48 92.97 4.10 4.05 11.2 157 
  SP12 46 M 2.77 89.71 8.90 9.10 5.1 197 
  SP13 40 M 2.57 57.64 4.30 4.50 11.9 140 
 SP14 45 M 2.37 91.40 6.08 7.90 7.0 181 
 SP15 41 F 2.56 64.86 5.19 5.62 11.3 143 
 SP16 44 F 2.63 92.19 9.31 9.50 4.2 218 
 SP17 39 M 2.36 85.16 5.27 5.53 10.4 157 
SP18 41 F 2.57 91.66 5.97 6.78 9.1 174 
SP19 45 F 2.54 93.55 5.09 5.58 10.2 155 
SP20 49 M 2.1 100.00 9.34 9.69 3.6 220 
SP21 40 F 2.5 95.00 5.41 5.83 14.9 151 
SP22 43 F 2.41 75.08 7.29 7.92 9.0 172 
SP23 38 M 2.8 94.50 5.80 6.38 9.4 168 
SP24 47 M 2.5 96.09 7.98 8.52 8.0 173 
SP25 39 F 2.74 77.32 6.05 6.73 10.1 168 
SP26 48 F 2.52 92.18 8.97 9.29 4.3 209 
SP27 39 F 2.68 49.78 4.10 4.25 13.0 132 
SP28 49 F 2.5 88.06 8.93 9.52 3.9 214 
SP29 41 F 2.35 92.06 5.51 6.01 9.0 168 
SP30 38 M 2.52 89.06 4.32 4.50 10.4 153 
      C39      38      F   0.5         4.60       2.25      0            7.9        106 
     C40      46      M   0.7         5.10       1.7      0          12.9          93 
     C41      50      F   0.6         6.50       1.6      0          21.0          87 
     C42      39      M    0.6         5.80       1.2      0          15.1          87 
     C43      51      F   0.6         6.10       2.4      0            6.5        109 
     C44      39      F   0.7         7.70       2.3      0            7.9        107 
     C45      54      F   0.7         7.60       2.2      0            8.9        103 
     C46      49      M   0.6         6.40       1.9      0          12.6          99 
     C47      39      M   0.7         7.60       2.25      0            6.3        107 
     C48      52      M   0.6         8.90       2.0      0            8.1        103 
     C49      48      F   0.6         9.10       2.3      0            8.3        108 
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SP31 50 M 2.44 67.16 8.81 9.81 3.8 215 
SP32 44 F 2.6 99.20 9.05 9.30 4.3 208 
SP33 41 F 2.11 96.02 8.45 8.93 5.1 195 
SP34 44 F 2.6 88.44 8.79 8.53 6.4 184 
SP35 42 M 2.5 98.17 6.13 6.33 6.9 181 
SP36 51 F 2.6 99.13 8.15 8.85 7.8 179 
SP37 47 M 2.1 91.70 8.97 9.41 5.1 192 
SP38 48 F 2.5 98.17 8.90 9.23 4.5 215 
SP39 42 M 2.23 93.21 6.95 7.10 7.4 184 
SP40 42 F 2.6 92.03 7.85 6.80 6.6 189 
SP41 41 F  2.5 95.00 6.53 5.53 9.1 181 
SP42 46 F 2.41 75.08 8.45 7.45 6.7 193 
SP43 49 M 2.8 94.50 8.45 9.29 4.4 204 
SP44 46 F 2.5 96.09 9.14 9.25 4.3 218 
SP45 47 M 2.74 77.32 9.51 9.98 3.5 227 
SP46 42 M 2.52 92.18 6.43 6.78 8.3 174 
SP47 38 M 2.68 49.78 5.58 5.83 10.5 155 
SP48 44 F 2.5 88.06 8.89 9.17 4.2 220 
SP49 40 M 2.35 92.06 5.78 6.37 9.3 167 
SP50 46 M 2.52 89.06 8.85 8.93 5.3 190 
 
 
           Table 3 : MASTER CHART - STUDY GROUP -II 
CASE 
NO 
AGE SEX PI % OF 
SITES BOP 
PPD 
(mm) 
CAL 
(mm) 
Adiponectin  
(µg/mL) 
FBS 
(mg/mL)  
PO1 40 F 0.8 7.50 1.55 1.65 13.4 145 
PO2 38 F 0.6 5.60 1.95 2.05 9.4 172 
PO3 43 F 0.7 6.80 2.69 2.98 8.9 177 
PO4 46 F 1.15 9.28 2.21 3.82 5.9 206 
PO5 44 M 0.8 5.99 2.17 2.46 6.8 189 
PO6 45 M 0.5 3.88 2.06 2.17 10.6 156 
PO7 40 M   0.85 7.45 2.18 2.28 9.2 168 
PO8 47 M 1.3 9.86 2.39 3.42 5.6 207 
PO9 43 M 0.6 6.50 2.16 2.20 6.4 178 
  PO10 45 F   0.75 5.75 1.90 2.0 10.5 161 
PO11 38 F 0.5 4.82 1.65 1.80 11.8 151 
PO12 46 M 0.9 8.10 1.95 2.55 6.5 183 
PO13 40 M 0.6 6.22 2.15 2.90 12.2 148 
PO14 45 M 0.8 8.48 2.00 2.85 8.0 173 
PO15 41 F 0.6 5.45 1.95 2.05 11.7 139 
PO16 44 F   0.98 11.93 2.01 3.55 4.7 211 
PO17 39 M 0.5  3.60 1.72 1.90 10.8 152 
PO18 41 F 0.7  8.20 1.85 2.50 9.6 169 
PO19 45 F 0.8  5.50 2.09 2.18 10.6 151 
PO20 49 M   1.35 11.95 2.74 3.90 6.3 201 
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PO21 40 F 0.5  5.17 1.61 1.83 15.4 148 
PO22 43 F 0.7  6.00 2.29 2.92 9.7 165 
PO23 38 M   0.45  5.50 2.30 2.32 9.9 163 
PO24 47 M   0.45  5.88 2.98 2.52 8.8 165 
PO25 39 F   0.65 11.10 2.05 2.73 10.4 166 
PO26 48 F 0.9  7.55 2.05 3.25 5.8 195 
PO27 39 F 0.6  6.65 1.50 1.80 13.1 131 
PO28 49 F   1.45  9.94 2.93 3.72 5.6 200 
PO29 41 F 0.5  4.00 1.90 2.25 9.7 162 
PO30 38 M 0.5  7.66 2.82 2.97 10.5 150 
PO31 50 M   0.55  9.95 2.81 3.91 5.6 201 
PO32 44 F 0.8  8.71 2.25 3.05 6.0 198 
PO33 41 F 0.6  4.00 2.45 2.93 6.1 186 
PO34 44 F 0.9  7.50 2.79 2.53 7.2 175 
PO35 42 M 0.7  6.50 2.93 2.53 7.5 176 
PO36 51 F 1.6 15.95 2.95 2.20 8.5 172 
PO37 47 M 0.6  9.40 2.29 3.10 5.8 183 
PO38 48 F 0.5  8.58 2.90 3.83 5.6 202 
PO39 42 M  0.74  5.00 2.95 2.0 8.4 177 
PO40 42 F      0.75        
4.60 
       6.50 2.15 3.17 7.0 183 
PO41 41 F       .58         7.80       
5.10 
2.22 2.52 9.1 178 
PO42 46 F      0.75         8.45       
6.50 
2.47 3.50 7.1 181 
PO43 49  M      1.35         9.65        
5.80 
2.05 3.25 5.8 194 
PO44 46 F      0.45       10.10        
6.10 
2.14 3.75 5.5 203 
PO45 47 M      0.7       11.45        
7.70 
2.51 3.98 5.7 204 
PO46 42 M      0.85        6.50       
7.60 
2.43 2.78 8.8 167 
PO47 38 M      0.92        5.45      
6.40 
1.90 2.20 10.7 151 
PO48 44 F      0.7        9.75      
7.60 
2.89 2.17 5.5 204 
PO49 40 M      0.5        6.00      
8.90 
1.95 2.70 9.9 162 
PO50 46 M      0.6        6.45          
9.10 
2.85 3.23 5.9 181 
  
 _______________________________________________________Results 
55 
 
          Table 4: Comparison of age between study and control group 
 Group N Mean Std. Deviation P-value 
Age (in  
years) 
Study 50 44.93 2.586 .073 
 (NS) Control 50 42.65 5.385 
       
NS - NOT SIGNIFICANT;  P >0.05 
 
      Table 5: Comparison of gender between study and control group 
 
 
 Group Total P-value 
 Study Control  
.501 
(NS) 
Sex 
 
Male 
Count 23 22 45 
% within Sex 51.1% 48.9% 100.0% 
% within Group 46.0% 44.0% 45.0% 
 
Female 
Count 27 28 55 
% within Sex 49.1% 50.9% 100.0% 
% within Group 54.0% 56.0% 55.0% 
Total 
Count 50 50 100 
% within Sex 50.0% 50.0% 100.0% 
% within Group 100.0% 100.0% 100.0% 
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Table 6: Comparison of clinical parameters between study  
group I and II  
 
Study group – I Study group - II 
P-value 
Mean SD Mean SD 
Plaque Index 2.494 0.147 0.987 0.079 
.000 
(S) 
% of sites 
with 
bleeding on 
probing 
90.407 5.385 7.563 2.289 
.000  
(S) 
 
P < 0.001; S-SIGNIFICANT 
 
        Table 7: Comparison of mean Adiponectin level between study                                        
                             group-I  and study group-II 
   Mean    N Std. Deviation Std. Error           
     Mean 
 Pair 1    CONTROL 
 
               PREOP     
                                                   
 Pair 2  CONTROL 
 
              POSTOP 
 
Pair 3    PREOP 
       
              POSTOP 
 
 
   15.0260  
 
     7.5200 
 
   15.0260  
 
     8.3900  
 
     7.5200 
 
     8.3900 
    50 
    50 
    50 
    50 
    50 
    50 
   7.92613 
   2.96090 
   7.92613 
   2.52411 
   2.96090 
   2.52411 
  1.12092 
   .41873 
  1.12092 
   .35696 
   .41873 
   .35696 
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    P <0.001; Sig – SIGNIFICANT (2-tailed) 
 
     Table 8:  Comparison of mean CAL between study group-I and                          
                                          study group-II 
 
             
P <0.001; Sig – SIGNIFICANT (2-tailed) 
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         Table 9: Comparison of mean PPD between study group-I and  
                                                study group-II 
 
                 
 P <0.001; Sig – SIGNIFICANT (2-tailed) 
  
           Table 10: Comparison of mean FBS level between study            
                                            group-I and study group-II 
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        Table 11: Correlation between clinical parameters, fasting blood                     
                    sugar and adiponectin level in study group I and II 
 
 
Adiponectin (µg/mL) 
Study group -I Study group – II 
PPD (mm) 
Correlation 
Coefficient 
-.795 -.390 
Sig. (2 tailed) .000 (S) .000 (S) 
N 50 50 
CAL (mm)  
Correlation 
Coefficient 
-.778 -.581 
Sig. (2 tailed) .000 (S) .000 (S) 
N 50 50 
FBS (mg/ml) 
Correlation 
Coefficient 
-.893 -.848 
Sig. (2 tailed) .000 (S) .000 (S) 
N 50 50 
      P <0.001; S – SIGNIFICANT (2-tailed) 
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      Figure 4: Comparison of age between Study and Control group 
 
          
 
 
 
      Figure 5:  Comparison of gender between Study and Control  
                                                   group 
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   Figure 6: Comparison of mean Plaque Index between Study  
                                      group I and II 
         
 
 
 
  Figure 7: Comparison of mean % of sites with BOP between Study              
                                              group I and II 
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    Figure 8: Comparison of mean adiponectin level in Study 
                                           group I and II 
          
 
 
 
 
Figure 9: Comparison of mean CAL between Study group I and II 
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  Figure 10: Comparison of mean PPD between Study group I and II 
 
           
 
 
 
        Figure 11: Comparison of mean FBS level between Study 
                                              group I and II 
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      Figure 12: Correlation of PPD and Adiponectin level in 
                                           Study group-I 
       
                          
                                                                                                             Linear (Adiponectin)          
 
      Figure 13: Correlation of PPD and Adiponectin level in  
                                           Study group-II 
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           Figure 14: Correlation of CAL and Adiponectin level in             
                                                  Study group-I 
                            
                                  
 
          
            Figure 15: Correlation of CAL and Adiponectin level in                   
                                                  Study group-II 
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          Figure 16: Correlation of FBS and Adiponectin level in  
                                                 Study group-I 
                                
 
  
           Figure 17: Correlation of FBS and Adiponectin level in 
                                                Study group-II 
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                                                            DISCUSSION 
The influence of Diabetes mellitus (DM) on periodontal disease has been 
discussed in the literature and also there is a substantial evidence to indicate that DM 
is a risk factor for periodontal disease. Conversely the effect of periodontal disease on 
glycemic control of diabetes has also been evaluated in many studies. 
In this study we have evaluated the effect of non surgical periodontal therapy 
(NSPT) on clinical periodontal parameters, fasting blood sugar (FBS) and serum 
adiponectin level in type-2 diabetes mellitus (T2DM) patients with moderate to severe 
chronic periodontitis. 
The mean FBS in healthy control is 94.5±9.176 mg/mL and the mean serum 
adiponectin level is 15.026±7.926 µg/mL. 
In the present study, non-surgical therapy was performed under local 
anesthesia by using ultrasonic devices and hand instruments which is consistent with 
Badersten et al
5 
who used hand instruments.      
The main finding of this study was the satisfactory clinical response to non 
surgical therapy, which was followed by a reduction in clinical parameters, FBS level 
and an increase in serum adiponectin level. Hence there was a linear negative 
correlation found between clinical periodontal parameters, FBS and serum 
adiponectin level.  
After initiation of the periodontal disease by putative subgingival pathogens, 
pro-inflammatory cytokines like TNF-α, IL-1 and IL-6 are produced in the local tissue 
as well as its levels are elevated in the circulation
45, 35
. TNF-α is an important 
inflammatory cytokine, closely linked to insulin resistance
11
 which regulates CRP 
expression. Studies showed that circulating TNF-α and CRP levels are increased in 
T2DM patients with chronic periodontitis
45, 35
. 
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In this present study, the mean PI value was 2.494 ± 0.147 in study group-I. 
There was a highly significant (p=0.000) reduction in mean PI value in study group-II 
(0.987± 0.079) when compared to study group-I. In study group-I the mean value of 
BOP was 90.407% ±5.385%, it was highly significantly (p=0.000) reduced to   
7.561% ±2.289% in study group-II. Similarly, the other clinical parameters, the mean 
PPD and CAL value respectively in study group-I were 7.13±1.738 mm and 
7.54±1.804 mm which was highly significantly (p=0.000) reduced respectively to 
2.283±0.423 mm and 2.740±0.655 mm in study group-II. All these findings were in 
line with Correa FOB et al
8
 and Kiran et al
23
 study. This significant reduction 
between study group-I and II is due to pro-inflammatory cytokines in the periodontal 
tissue as mentioned above. 
In this study, the non surgical therapy was performed without changing the 
anti-diabetic treatment including drugs and diet in study group-I subjects. Fasting 
blood sugar level was used as a measure of glycemic control, the mean FBS level in 
study group-I was 183.20±24.982 mg/mL when compared to group-II which was 
highly significantly (p=0.000) reduced to 175.20±20.360 mg/mL. This finding is in 
accordance with Wei-Lian Sun et al
50
 who reported that moderate to poorly 
controlled T2DM patients with chronic periodontitis after periodontal intervention 
exhibited a significant reduction in FBS level. 
Previous studies mentioned conflicting results on whether the non surgical 
therapy has impact on the glycemic control in T2DM. In the present study, we 
observed PPD, CAL and FBS level were significantly decreased in the study group-II 
as compared to study group I. These results confirmed that the non surgical therapy 
reduces clinically evident inflammation thereby reducing the insulin resistance
11
 and 
improving glycemic control in T2DM. These findings indicate that inflammation is 
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involved in the pathogenesis of insulin resistance (IR) and T2DM, which is regarded 
as main processes in the mechanism of T2DM
4
.   
Adiponectin is the only adipocytokine exclusively secreted by adipose tissue, 
which profoundly influences insulin sensitivity by inhibiting glucose uptake by 
adipose tissue and muscle
52
. In the present study there was a highly significant 
(p=0.000) increase in adiponectin level 8.39±2.52µg/mL in study group-II, when 
compared to study group-I who had 7.52±2.96µg/mL. This finding is in concurrence 
with Pariksha Bharti et al
36
 and Kardesler et al
22
, who had also found elevation of 
serum adiponectin level after periodontal treatment. Another study by Hotta et al
16
, 
reported that type-2 diabetic patients had relatively lower serum adiponectin 
concentrations compared with non-diabetic patients which is similar to this study 
because we have found lower serum adiponectin level in T2DM (study group-I) 
patients compared with healthy controls who had 15.026±7.926 µg/mL. 
We hypothesized that the non surgical therapy improves insulin sensitivity due 
to the elevation of adiponectin levels
52, 39
. The present study showed that there was an 
elevation of serum adiponectin level and a negative correlation found between the 
serum adiponectin level, clinical periodontal parameters and FBS level. 
According to the present study there was a highly significant (p=0.000) 
elevation of serum adiponectin level in study group-II compared to study group-I. 
This is in partial accordance with Matsumoto et al
31
, who investigated the effects of 
anti microbial periodontal treatment (APT) on serum adiponectin level in T2DM 
patients with chronic periodontitis. Their results showed improvement periodontal 
conditions and increased serum adiponectin level, 2 months after periodontal 
treatment. 
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Hence, periodontal intervention helps in improving the glycemic control and 
insulin sensitivity which may be associated with decreased serum inflammatory 
cytokines and increased serum adiponectin level. The underlying mechanism of these 
inflammatory cytokines still remains unclear. However, Nishimura et al
35
 found that 
chronic periodontal inflammation can lead to increased serum levels of TNF-α, thus 
inducing the phosphorylation of serine residues in the insulin receptor substrate-1, 
promoting the target cells to produce insulin resistance also acting on the liver to 
increase CRP synthesis. Many investigators suggested that TNF-α and other 
inflammatory cytokines may activate the intercellular pathways such as the I-kappa-B 
(IκB), I-kappa-B kinase (IκKB), nuclear factor-kappa B (NF-κB) and the protein c-
Jun N-terminal kinase (JNK) axes, amplify and aggravate low-grade inflammation. 
These processes may become self-perpetuating through a positive feedback loop 
created by the pro-inflammatory cytokines and lead to insulin resistance and diabetes. 
 The mechanism for increased adiponectin could be through reduction of 
bacterial endotoxins (LPS) by periodontal treatment ameliorates the burden on 
immune system in adipose tissues, which led to the elevation of serum adiponectin 
levels
36
. Toll-like receptor ligands causes pro-inflammatory and pro-diabetic 
activation of adipocytes via c-Jun N-terminal Kinase (JNK)
24
 and selective 
inactivation of JNK in adipose tissue-specific over expression of dominant-negative 
JNK transgenic mice
54
. These results suggested that the periodontal treatment 
increases serum adiponectin levels by reducing the influence of toll-like receptor 
ligands (such as LPS) from the inflamed periodontal tissue. 
In the present study, there was statistically highly significant increase in serum 
adiponectin level in type-2 diabetes mellitus patients with moderate to severe chronic 
periodontitis 3 months after the non surgical therapy (study group II) as compared to 
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base line (study group I). There was highly significant decrease in fasting blood 
glucose level and periodontal clinical parameters observed 3 months after therapy. 
Therefore the effect of non surgical therapy on serum level of adiponectin is 
predictable and significant association was observed in type-2 diabetes mellitus with 
periodontal inflammation. 
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                                               SUMMARY AND CONCLUSION    
 
            In the present study totally hundred subjects attending the Department of 
Periodontics were recruited. Out of the hundred subjects, fifty age and gender 
matched subjects with healthy periodontium were the control group, fifty type-2 
diabetes mellitus patients with moderate to severe chronic periodontitis were the study 
group. 
            All the subjects have been examined to assess periodontal clinical parameters 
such as Plaque index, Bleeding on probing, Pocket probing depth and Clinical 
attachment level and were recorded. Fasting blood sugar was evaluated using 
glucometer for all the subjects and recorded. Venous blood was drawn for all hundred 
subjects and serum adiponectin level was analysed using ELISA method. Fifty type-2 
diabetic with chronic periodontitis patients underwent non-surgical periodontal 
therapy using ultra-sonic scalers and hand instruments and put on maintenance for 
three months. After three months, periodontal status was reevaluated. Fasting blood 
sugar was estimated using glucometer and serum adiponectin level was analysed 
using ELISA method. 
            The findings are summarized as follows 
1. In the healthy age and gender matched control group with healthy periodontium, 
the serum adiponectin level was 15.02±7.926µg/mL. 
2. In type-2 diabetes mellitus with chronic periodontitis patients before non-surgical 
therapy (Study group-I) had decreased serum adiponectin level and the mean value 
being 7.52±2.96µg/mL. 
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3. In type-2 diabetes mellitus with chronic periodontitis patients three months after 
non-surgical therapy (Study group-II) had improvement in periodontal clinical 
parameters and a highly significant (p=0.000) increase in serum adiponectin level 
which was 8.39±2.52 µg/mL. 
           We would like to hypothesize that in this present study, non-surgical 
periodontal therapy improves periodontal status thereby increases serum adiponectin 
level in type-2 diabetes mellitus patients with moderate to severe chronic 
periodontitis.  
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       PROFORMA 
 
Date:  Dental OP No:          Code No: 
Name: Age/ Sex:          Occupation: 
Address: Income:          Tel. No: 
CHIEF COMPLAINTS 
Pain/Shaky teeth/ Bleeding gums/ swollen Gums/ Receding Gums/ Pus 
Discharge/ Increase in Spacing between teeth/ stains/ others. 
Duration: 
 
Medical History: 
Any relevant Medical History. 
Family History: 
Any familial relevant Medical History.  
Dental History: 
Periodontal treatment within past 6 months.  
Personal History: 
History of Smoking, Consumption of Alcohol  
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PLAQUE INDEX – SILNESS & LOE (1964) 
|  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | 
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
|  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  | 
Calculation: 
 
Inference: 
 
GINGIVAL BLEEDING INDEX – AINAMO & BAY (1975) 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
Inference 
PROBING DEPTH (PD) & CLINICAL ATTACHMENT LEVEL (CAL)  
(in mm) 
Maxillary 
     Palatal 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
     Buccal 
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MANDIBULAR 
 
     Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
    Buccal 
INVESTIGATION: 
OPG 
Complete Blood Count: Hb%, CT, BT, TC, DC 
DIAGNOSIS: 
Laboratory Analysis 
 RESULT:                                                      Date:   Time: 
1. Fasting Blood Sugar:  (Reference Value: 80-110mg/dl) 
2. Adiponectin :   (Reference Value: 5-30mcg/ml) 
   
AFTER PHASE-I THERAPY 
GINGIVAL BLEEDING INDEX – AINAMO & BAY (1975) 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
Inference 
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PROBING DEPTH (PD) & CLINICAL ATTACHMENT LEVEL (CAL)  
(in mm) 
 
Maxillary  
                                                   Palatal 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
     Buccal 
MANDIBULAR 
     Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
    Buccal 
Laboratory Analysis 
   RESULT:                                                                        Date:                     Time: 
1. Fasting Blood Sugar:           (Reference Value: 80-110mg/dl) 
2. Adiponectin:    (Reference Value: 5-30mcg/ml) 
 
       
Signature of the PG student                                  Signature of the Guide 
Date : 
Time : 
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INFORMED CONSENT FORM 
Study Title 
EVALUATION OF SERUM ADIPONECTIN LEVELS IN TYPE-II 
DIABETES MELLITUS WITH CHRONIC PERIODONTITIS- AN 
INTERVENTIONAL STUDY 
Name: O.P.No: 
Address: Code No: 
 Age/ Sex: 
 Tel. No: 
I, ________________________________ age ______ years exercising 
my free power of choice, hereby give my consent to be included as a 
participant in the study “Evaluation of serum adiponectin levels in type-ii 
diabetes mellitus with chronic periodontitis- an interventional study” 
I agree to the following: 
 I have been informed to my satisfaction about the purpose of the study and 
study procedures including investigations to monitor and safeguard my 
body function. 
 I understand that the lab investigations will require the procurement of my 
blood in required amount. 
 I agree to cooperate fully and to inform my doctor immediately if I suffer 
any unusual symptom. 
 I have informed the doctor about all medications I have taken in the recent 
past and those I am currently taking. 
 I hereby give permission to use my medical records for research purpose. I 
am told that the investigating doctor and institution will keep my identity 
confidential. 
 
Name of the Patient   Signature/ Thumb Impression 
 
Name of the Investigator    Signature   Date 
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INFORMATION SHEET 
 We are conducting a study on “Evaluation of Serum Adiponectin 
levels in Type-II Diabetes Mellitus with chronic Periodontitis – An 
Interventional Study” among patients attending TNGDCH, Chennai 
and for this study, we are selecting patients.  
 The identity of the patients participating in the research will be kept 
confidential throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared 
 Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision 
will not result in any loss of benefits to which you are otherwise 
entitled. 
 The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal 
which may aid in the management or treatment.  
 
 
Name of the patient  Signature/Thumb impression 
 
 
Name of the investigator   Signature   Date 
